One of the key features that distinguishes preclinical studies performed at CAPR is the use of immune-proficient genetically engineered mouse models (A detailed list can be found here: https://ccr.cancer.gov/center-for-advanced-preclinical-research/capr-models). Importantly, we leverage our large, diverse mouse colony and access to advanced tumor imaging modalities to breed, randomize, and enroll statistically powered study cohorts that yield more clinically predictive results than smaller studies can achieve.
Our expertise includes the development of novel GEM-derived allograft models (GDA) that are well suited for preclinical studies.
The range and scope of projects vary from testing the tolerability and efficacy of therapeutic compounds or cell-based therapeutics, to the development and characterization of novel cancer mouse models, and participating in co-clinical trials for simultaneous evaluation of drug response in patients and in mouse models, including generation of patient-derived xenografts (PDXs).
Our board-certified pathologist performs thorough biomarker characterization on in-house generated immunohistochemistry (IHC) and immunofluorescent (IF) stained sections utilizing AI-supported automated high-content image analyses and quantification tools available at CAPR.
We work closely with all core facilities on both Frederick campuses.
Select publications illustrating our capabilities can be found here: https://ccr.cancer.gov/center-for-advanced-preclinical-research/capr-publications
Genetically Modified Mouse Models
A detailed list of CAPR cancer mouse models can be found here: https://ccr.cancer.gov/center-for-advanced-preclinical-research/capr-publications
In Vivo Capabilities
In Vitro Capabilities
CAPR is not a Core and does not accept requests as such. Each year, we onboard new projects through a CCR-wide request for application (RFA) announcement (a sample RFA document is here: https://ccrod.cancer.gov/confluence/display/CC/2021+RFA). The CAPR Oversight Committee, in consultation with CAPR scientists, reviews and scores the proposals to select 5-8 new projects for their scientific merit, novelty, feasibility, and potential to accelerate cancer treatment, prevention or detection. These projects can vary widely in scope but take an average of about 18 months to complete. We may also carry out isolated pilot or proof of concept studies when appropriate and as workload allows.
Please reach out to the contacts above for more information.